NYMXF (Nymox Pharmaceutical) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


What is Nymox Pharmaceutical Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Nymox Pharmaceutical's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

NYMXF vs LYRA, RNAZ, TOVX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Nymox Pharmaceutical's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nymox Pharmaceutical Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Margin of Safety % (DCF Earnings Based) falls into.


Nymox Pharmaceutical Business Description

Address Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and low-grade localized prostate cancer. The company also has an extensive patent portfolio covering its investigational drug as well as other therapeutic and diagnostic indications. It also has U.S. and patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The company operates in one reportable segment, focused on researching and developing products for the aging population.